Psilocybin, the active compound in hallucinogenic mushrooms, is edging into mainstream psychiatry in parts of Europe – with Switzerland already treating patients and the Czech Republic opening tightly supervised therapies. But France is holding back, limiting its use to clinical trials while doctors wait for stronger evidence of its efficacy.
Belarus: Snow and cold used to torture political prisoners
...
Read moreDetails
